Eli Lilly and Insilico Medicine Seal $2.75B AI Drug Discovery Partnership After FTC Clearance

Eli Lilly and Company has cleared U.S. antitrust review for its licensing and research partnership with Insilico Medicine, clearing a key regulatory hurdle for one of the largest recent collaborations in AI-driven drug discovery. According to a Federal Trade Commission filing (Transaction ID: 20261000) dated March 26, 2026, the agency granted early termination of the waiting period under the Hart–Scott–Rodino Act, allowing the deal to proceed. The clearance paved the way for a partnership that Insilico announced on March 29 could be worth up to $2.75 billion, including $115 million upfront from Lilly.

A Multi-Billion-Dollar AI Partnership with Eli Lilly

Under the agreement, Lilly will receive exclusive worldwide rights to develop, manufacture and commercialize selected preclinical AI-discovered oral drug candidates from Insilico. The companies will also collaborate on new research programs using Insilico’s generative AI platforms.

“Insilico’s AI-enabled discovery capabilities represent a powerful complement to Lilly’s deep expertise in clinical development across multiple therapeutic areas,” said Andrew Adams, Group Vice President of Molecule Discovery at Lilly. “This collaboration allows us to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas.”

Commercial Momentum and AI Ambitions of Insilico

The deal arrives as Insilico pushes ahead with business development under founder and CEO Alex Zhavoronkov.. The partnership is expected to accelerate revenue growth, advance more preclinical candidates and broaden deployment of the company’s multimodal AI platform, MMAI Gym.

In a statement, Zhavoronkov said the collaboration underscores Insilico’s ability to produce novel molecular designs in a highly competitive AI-biotech landscape. He also noted a personal connection to Lilly, saying he is a patient using the company’s therapies.

It has developed at least 28 drugs using generative AI tools, with nearly half already at a clinical stage. “Working with Lilly, we aim to deliver transformative therapies that treat diseases with high unmet need. This collaboration is a testament to the power of AI in tackling the most complex challenges in human health. In many ways, Lilly is better than us in some areas of AI,” Zhavoronkov said, noting the U.S. pharma giant has “one person” who has brought biology, chemistry and automation under one roof. He added that as part of the deal, Insilico will join Lilly’s Gateway Labs community for biotech development.

Looking ahead, it is prioritizing development of foundation models for scientific discovery in 2026. By integrating those models with Lilly’s global research and development infrastructure, the two companies aim to shorten the time and lower the cost of traditional drug discovery.

The FTC’s early termination removes the standard 30-day waiting period, enabling the partnership to move forward as large pharmaceutical companies intensify efforts to build AI-enabled pipelines.

Author

Steven Chung

紅杏枝頭春意鬧固然是眾人所追求的風景，但我願意說，青蘿拂行衣更能湧生感嘆。 願在海量晦澀的生醫資訊中，為您點亮一座心燈塔。鐘煌翔